We reported that atorvastatin, but not pravastatin, inhibited the "platelet antiaggregatory effect of clopidogrel in a dosedependent manner." 1 We offered no data on how the atorvastatin-clopidogrel drug-drug interaction might influence clinical outcomes. This subject requires additional evaluation.
Response
We reported that atorvastatin, but not pravastatin, inhibited the "platelet antiaggregatory effect of clopidogrel in a dosedependent manner." 1 We offered no data on how the atorvastatin-clopidogrel drug-drug interaction might influence clinical outcomes. This subject requires additional evaluation.
In the first part of our study, the numbers of patients on aspirin therapy before and after percutaneous coronary intervention (PCI) were as follows: (1) In the clopidogrel group, 14 of 16 (87%) patients were receiving aspirin therapy prior to PCI, and 100% were receiving aspirin (325 mg) after PCI for life; (2) in the clopidogrel ϩ pravastatin group, 9 of 9 (100%) patients were receiving aspirin therapy prior to PCI and 100% after PCI for life; and (3) in the clopidogrel ϩ atorvastatin group, 18 of 19 (95%) patients were receiving aspirin therapy prior to PCI and 100% after PCI for life. Blood samples for the second platelet aggregation test were all obtained after aspirin administration. These data suggest that the observed interference of the platelet antiaggregatory effect of clopidogrel by atorvastatin was independent of aspirin therapy.
In the two subsequent studies, stringent exclusion criteria, including ingestion of other antiplatelet agents, were applied to healthy volunteer subjects to alleviate potential confounding variables in the assessment of the antiaggregatory effect of clopidogrel.
Finally, aspirin exerts its effect primarily by interfering with the biosynthesis of thromboxane A 2 , 2 whereas clopidogrel inhibits the GTP inhibitory (G i ) protein-coupled P2Y 12 ADP receptor. 3 We did not specifically test for the platelet inhibitory effect of aspirin; we tested for the platelet antiaggregatory effect of clopidogrel by using 20 mol/L ADP as the agonist.
